US Imposes 100% Tariffs on Patented Medicines, Offers Deals to Manufacturers
The US government has announced a 100% tariff on patented medicines entering the country. This measure, ordered by President Donald Trump, is intended to incentivise the domestic manufacturing of key medicines and mitigate national security vulnerabilities.
Tariff Avoidance and Strategic Agreements
Despite the high tariff rate, pharmaceutical companies have avenues to avoid these levies. Firms committing to new manufacturing operations within the US before January 2029 will face a reduced 20% tariff. This can further decrease to zero if companies agree to specific pricing deals with the government, often involving selling medicines to US government health insurance programmes at rates comparable to certain overseas markets.
Many prominent drug manufacturers have already secured agreements to bypass these tariffs, with more expected to follow. Sean Sullivan, a professor at the University of Washington and London School of Economics, highlighted the strategic intent: “The goal is to bring the rest of the companies to the bargaining table. It's all about leverage.”
Exemptions and International Pacts
Crucially, these tariffs do not apply to generic medicines, which constitute the majority of prescriptions in the US. Furthermore, existing lower tariff agreements with key international partners, including Europe, Switzerland, the UK, South Korea, and Japan, will be honoured.
Last December, the UK and US finalised a deal ensuring zero tariffs on UK pharmaceutical shipments to America for three years. In exchange, the UK committed to increased medicine procurement costs for the NHS. The UK government hailed this as a significant win for British patients and businesses, anticipating stronger incentives for companies to launch new treatments in the UK sooner.
Senior US administration officials have indicated that large companies have 120 days to negotiate agreements, while small and medium-sized enterprises are granted 180 days. The White House claims the threat of tariffs has already prompted pharmaceutical firms to pledge an additional $400bn in US investments.
Uncertainty and Potential Impact
Richard Frank, a senior fellow at the Brookings Institution, expressed reservations about the order's precise impact, noting the ambiguity surrounding potential exemptions and the number of companies that will ultimately strike deals. While larger firms may already be insulated, smaller businesses could face significant cost increases. Frank cautioned, “the devil really is the details and what sounds really good in a press release may not look the same when it actually hits the ground.”
